KRAS and colorectal neoplasm: To evaluate technical performances of the newly developed platform and verify its ability to correct genotyping of KRAS and BRAFV600E mutations in colorectal tumor samples, we selected 60 tissue samples already classified for these genetic variants by complete protocols of conventional and COLD-PCR, High Resolution Melting analysis and direct sequencing.